DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 398

131. Marinelli RA, Tietz PS, Larusso NF. 2005. Regulated vesicle trafficking of membrane
transporters in hepatic epithelia. J Hepatol 42(4):592-603.
132. Wakabayashi Y, Lippincott-Schwartz J, Arias IM. 2004. Intracellular trafficking of bile
salt export pump (ABCB11) in polarized hepatic cells: constitutive cycling between
the canalicular membrane and rab11-positive endosomes. Mol Biol Cell 15(7):3485-
3496.
133. Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KLR. 2006. Hep-
atobiliary disposition of a drug/metabolite pair: comprehensive pharmacokinetic
modeling in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 318(2):881-
889.
134. Tahara H, Kusuhara H, Fuse E, Sugiyama Y. 2005. P-glycoprotein plays a major role
in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a
limited role in its biliary excretion. Drug Metab Dispos 33(7):963-968.
135. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE,
Webster LO, Bridges AS, Kalvass JC, Brouwer KLR. 2005. Multiple mechanisms are
involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and
Bcrp1. Drug Metab Dispos 33(8):1158-1165.
136. Doherty MM, Poon K, Tsang C, Pang KS. 2006. Transport is not rate-limiting in
morphine glucuronidation in the single-pass perfused rat liver preparation. J Pharmacol
Exp Ther 317(2):890-900.
137. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue
distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery
and activity in cancer chemotherapy. Mol Carcinog 13(3):129-134.
138. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, Thakker
DR. 1996. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of
cyclosporin A in Caco-2 cells. Drug Metab Dispos 24(3):344-349.
139. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and
P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Drug Metab Dispos 27(8):866-871.
140. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. 2002. Interac-
tion of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther
303(1):323-332.
141. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P. 1999. Interplay between
CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in
intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 16(5):625-632.
142. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. 2000. Influence of P-
glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing
cytochrome P-450 3A4. J Pharmacol Exp Ther 292(1):310-318.
143. Wu CY, Benet LZ. 2003. Disposition of tacrolimus in isolated perfused rat liver: in-
fluence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos 31(11):1292-
1295.
144. Jeong H, Chiou WL. 2006. Role of P-glycoprotein in the hepatic metabolism of
tacrolimus. Xenobiotica 36(1):1-13.
145. Lau YY, Wu CY, Okochi H, Benet LZ. 2004. Ex situ inhibition of hepatic uptake
and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J
Pharmacol Exp Ther 308(3):1040-1045.